Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing the availability of final product-specific bioequivalence (BE) recommendations. The recommendations provide product-specific guidance on the design of BE studies to support abbreviated new drug applications (ANDAs). In the Federal Register of May 31, 2007, FDA announced the availability of a draft guidance for industry entitled “Bioequivalence Recommendations for Specific Products” explaining the process that would be used to make product-specific BE recommendations available to the public on FDA's Web site. The BE recommendations identified in this notice were developed using the process described in that guidance. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of additional draft and revised draft product-specific BE recommendations.
Submit written or electronic comments on agency guidances at any time.
Submit written requests for single copies of the individual BE guidances to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the product-specific BE recommendations to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.regulations.gov. See the SUPPLEMENTARY INFORMATION section for electronic access to the recommendations.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Doan T. Nguyen, Center for Drug Evaluation and Research (HFD-600), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9314.End Further Info End Preamble Start Supplemental Information
In the Federal Register of May 31, 2007 (72 FR 30388), FDA announced the availability of a draft guidance for industry entitled “Bioequivalence Recommendations for Specific Products” that explained the process that would be used to make product-specific BE recommendations available to the public on FDA's Web site at http://www.fda.gov/cder/guidance/bioequivalence/default.htm. As described in that draft guidance, FDA adopted this process as a means to develop and disseminate product-specific BE recommendations and provide a meaningful opportunity for the public to consider and comment on those recommendations. Under that process, draft recommendations are posted on FDA's Web site and announced periodically in the Federal Register. The public is encouraged to submit comments on those recommendations within 90 days of their announcement in the Federal Register. FDA considers any comments received and either publishes final recommendations, or publishes revised draft recommendations for comment. Once finalized, the recommendations are posted on FDA's Web site and announced in the Federal Register. This notice announces product-specific recommendations that have been posted on FDA's Web site from May 1, 2008, through October 31, 2008. Additional draft and revised draft product-specific BE recommendations are being announced elsewhere in this issue of the Federal Register.
II. Drug Products for Which Final Product-Specific BE Recommendations Are Available
FDA is announcing final BE product-specific recommendations for drug products containing the following active ingredients:
Abacavir Sulfate; Lamivudine; Zidovudine
Amlodipine Besylate; Benazepril HCl
Amoxicillin; Clavulanate Potassium
AprepitantStart Printed Page 27149
Bisoprolol Fumarate; Hydrochlorothiazide
Desloratadine (multiple dosage forms)
Diclofenac Sodium; Misoprostol
Didanosine (multiple dosage forms)
Donepezil HCl (multiple dosage forms)
Efavirenz (multiple dosage forms)
Famotidine (multiple dosage forms)
Fenofibrate (multiple dosage forms)
Fluoxetine HCl; Olanzapine
Glipizide; Metformin HCl
Glyburide; Metformin HCl
Hydrochlorothiazide; Losartan Potassium
Hydrochlorothiazide; Olmesartan Medoxomil
Isradipine (multiple dosage forms)
Lamotrigine (multiple dosage forms)
Meloxicam (multiple dosage forms)
Metformin HCl; Pioglitazone HCl
Omeprazole; Sodium Bicarbonate
Oxcarbazepine (multiple dosage forms)
Phenytoin Sodium (multiple dosage forms)
Ribavirin (multiple dosage forms)
Risedronate Sodium; Calcium Carbonate
Tramadol HCl; Acetaminophen
Verapamil HCl (multiple reference listed drug (RLDs))
Zidovudine (multiple dosage forms)
For a complete history of previously published Federal Register notices, please go to http://www.regulations.gov and enter docket number FDA-2007-D-0369.
These guidances are being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidances represent the agency's current thinking on product-specific design of BE studies to support ANDAs. They do not create or confer any rights for or on any person and do not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.
Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments on any of the specific BE recommendations posted on FDA's Web Start Printed Page 27150site. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The guidance, notices, and received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
IV. Electronic AccessStart Signature
Dated: May 27, 2009.
Associate Commissioner for Policy and Planning.
[FR Doc. E9-13261 Filed 6-5-09; 8:45 am]
BILLING CODE 4160-01-S